How we make money & how we rank

Peptide Samplesis reader-supported. We earn affiliate commissions from a subset of the peptide clinics and telehealth providers we list when readers sign up through our links. Rankings are earned by the clinic, not the deal — clinics don't pay for placement, clinics don't see content before publication, and we don't run sponsored content disguised as editorial. Whether a clinic pays us $0 or $400 per intake never enters the rubric. Here is exactly how the money flows and what it does (and does not) influence.

The two-track architecture (peptidesamples-specific)

Peptide therapy spans FDA-cleared products (tesamorelin / Egrifta, PT-141 / Vyleesi) all the way to Category 2 research-only molecules (BPC-157, TB-500, melanotan-2). We split our coverage into two tracks with different posture for each:

• Clinical track — peptides with a legal Rx route (sermorelin, ipamorelin, CJC-1295, tesamorelin, PT-141, GHK-Cu, MK-677 educational reframe, thymosin alpha-1). We link to vetted telehealth providers and specialty clinics that prescribe through licensed clinicians and 503A pharmacy partners. Affiliate commissions on this track.
• Educational track — Cat-2 / research-only peptides (BPC-157, TB-500, plus the Phase 3 backlog: melanotan-2, epitalon, DSIP, etc.). These pages have NO vendor links. The only CTA is a clinician conversation routed through clinical providers (Marek, Defy, Eden, GobyMeds). We do not link to research- chemical vendors regardless of their RUO disclaimers.

The money flow

When you click a tracked outbound link on a Clinical-track page and start an intake or order labs through one of our listed providers, the provider may pay us a commission. Some relationships are direct with the provider, others are through affiliate networks (CJ Affiliate, Impact, Awin, ShareASale). The commission is paid by the provider, not by you — your price is the same whether you click our link or go direct.

Not every provider on this site is an affiliate partner. We list providers we have not partnered with when we think they are best for the reader. Specialty peptide clinics that work primarily on physician referral are listed for editorial completeness even where no affiliate program exists.

What compensation does not change

• Ranking order. Position is computed from a weighted blend of editor rating, reader-verified trust score, last-verified recency, clinical depth (lab cadence, full peptide formulary, TRT + peptide integration), and pricing transparency. Commission rate is not a factor.
• Whether we cover a provider. If a provider is relevant to readers, we cover them — partner or not.
• What we say in a review. Negative findings stay in the review even when the provider pays us.
• Educational-track posture. Affiliate revenue cannot buy a research-chemical vendor a link on a Cat-2 peptide page. The no-vendor-link rule is absolute.

Editorial methodology — how we rank

Every clinical-track peptide provider on this site is scored on the same five-factor rubric.

1. Editor rating (0–5). Our editorial team reviews the intake, the prescribing protocol, lab cadence, and adjunct-therapy availability for every clinic we list. Ratings reflect: clinical depth of intake, monitoring discipline (IGF-1, fasting metabolic panel, hormone optimization quarterly minimum), protocol flexibility (sermorelin / ipamorelin / CJC-1295 with/without DAC; oral vs injection; TRT + peptide integration), transparency of pricing.
2. Reader-verified trust score.Real readers vote "trust" or "don't trust" on a provider after they've used it. Provider pages display the live tally.
3. Last-verified recency. Pricing, formularies, and provider terms change frequently. We re-verify weekly.
4. Program-specific signals.Peptide formulary breadth, state coverage, 503A pharmacy network, integrated hormone-optimization capability, women's patient experience.
5. Pricing transparency. A provider that publishes clear all-in monthly pricing (consult + medication + supplies + quarterly labs) scores higher than one that hides component costs.

Our commitments

• We will list providers we have not partnered with when they are best for the reader.
• We will surface negative findings even when a partner pays us.
• We will delist a provider if quality, compliance, or accuracy drops — even when it costs us revenue.
• Every provider page shows a last-verified date.
• We will not publish dosing protocols. The April 2026 FDA enforcement action against 7 peptide RUO sites clarified that dosing-implication content is the line that triggers drug-misbranding enforcement. We discuss mechanism, regulatory status, cost paths, and clinical alternatives — not dosing.
• We will not link to research-chemical vendors on educational-track pages, regardless of their RUO disclaimers.
• We will not pipe answers from the eligibility quiz into Meta Pixel, GA4 custom dimensions, or any third-party ad pixel. (After the FTC $1.5M GoodRx enforcement action, this is the line.)

What we are not

Peptide Samples is an editorial directory. We are not a prescriber, telehealth platform, pharmacy, or pharmaceutical manufacturer. We do not provide medical advice, diagnose conditions, prescribe medications, or fulfill prescriptions. Peptide therapy requires a clinical evaluation by a licensed clinician — we cannot and do not substitute for that conversation. Use of this site does not create a doctor–patient relationship. The eligibility quiz is an editorial directory filter — its output is a provider match, not a clinical recommendation, diagnosis, or treatment plan. See our full medical disclaimer.

Affiliate networks & partners

Active affiliate relationships are managed through CJ Affiliate, Impact, Awin, and ShareASale, plus a handful of direct-to-provider relationships (Marek Health, Eden, AgelessRx, Tailor Made Compounding, LIVV Natural). The list of programs we run changes; the per-row "Affiliate" tag and last-verified date on every listing are the freshest signal of which providers are partners.

Have a concern?

If you spot something on this site that seems wrong — outdated pricing, a provider you believe should be downgraded, a reader complaint pattern — email editorial@peptidesamples.com. We read every message and update the site within 7 days for anything material.

Last reviewed: 2026-05-18 · Peptide Samples Editorial Team · Independent editorial publication. property.